{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:46:37Z","timestamp":1792431997482,"version":"4.5.0"},"reference-count":56,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2017,5,22]],"date-time":"2017-05-22T00:00:00Z","timestamp":1495411200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2017,5,22]],"date-time":"2017-05-22T00:00:00Z","timestamp":1495411200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008271","name":"LEO Pharma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008271","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Although the majority of patients with psoriasis vulgaris are treated exclusively with topical therapies, research to develop more effective topical therapies that are associated with higher patient satisfaction has lagged behind the development of systemic agents. The aim of this literature review was to determine whether there is documented evidence that applying an innovative approach to improving the formulation of active ingredients commonly used in the topical treatment of psoriasis can have a positive effect on clinical outcomes and patient\u2010reported outcomes (\n                    <jats:styled-content style=\"fixed-case\">PRO<\/jats:styled-content>\n                    s). The Embase and PubMed databases were searched for articles published between 2001 and 2016 that made direct head\u2010to\u2010head comparisons of different formulations of an active pharmaceutical ingredient (\n                    <jats:styled-content style=\"fixed-case\">API<\/jats:styled-content>\n                    ), focusing on clinical outcomes and\n                    <jats:styled-content style=\"fixed-case\">PRO<\/jats:styled-content>\n                    s. In total, 22 publications on\n                    <jats:styled-content style=\"fixed-case\">API<\/jats:styled-content>\n                    s or\n                    <jats:styled-content style=\"fixed-case\">API<\/jats:styled-content>\n                    combinations met the eligibility criteria (19 head\u2010to\u2010head clinical trials, one pooled analysis, one health\u2010economic modelling study and one systematic review). Significant clinical benefit associated with the use of a reformulated\n                    <jats:styled-content style=\"fixed-case\">API<\/jats:styled-content>\n                    over an older formulation was reported in three trials of clobetasol propionate, one trial of calcipotriol, three trials of betamethasone and five trials\/pooled analyses of calcipotriol\/calcipotriene + betamethasone dipropionate (Cal\/\n                    <jats:styled-content style=\"fixed-case\">BD<\/jats:styled-content>\n                    ) formulations. Significantly improved\n                    <jats:styled-content style=\"fixed-case\">PRO<\/jats:styled-content>\n                    s associated with the use of a reformulated\n                    <jats:styled-content style=\"fixed-case\">API<\/jats:styled-content>\n                    over an older formulation were reported in three trials of clobetasol propionate, one trial of betamethasone valerate and two trials of Cal\/\n                    <jats:styled-content style=\"fixed-case\">BD<\/jats:styled-content>\n                    formulations. These results demonstrate that the innovative reformulation of\n                    <jats:styled-content style=\"fixed-case\">API<\/jats:styled-content>\n                    s used in the treatment of psoriasis can produce therapies that attain significantly improved clinical outcomes and\n                    <jats:styled-content style=\"fixed-case\">PRO<\/jats:styled-content>\n                    s. This suggests that improvement in topical therapy for psoriasis need not only to be achieved by the identification of new targets and the development of new\n                    <jats:styled-content style=\"fixed-case\">API<\/jats:styled-content>\n                    s, but that improvement in the vehicle used to deliver existing\n                    <jats:styled-content style=\"fixed-case\">API<\/jats:styled-content>\n                    s has the potential to result in significant clinical and patient benefits.\n                  <\/jats:p>","DOI":"10.1111\/jdv.14277","type":"journal-article","created":{"date-parts":[[2017,4,17]],"date-time":"2017-04-17T14:16:41Z","timestamp":1492438601000},"page":"1271-1284","source":"Crossref","is-referenced-by-count":26,"title":["Reformulations of well\u2010known active ingredients in the topical treatment of psoriasis vulgaris can improve clinical outcomes for patients"],"prefix":"10.1111","volume":"31","author":[{"given":"L.","family":"Iversen","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology Aarhus University Hospital Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Dauden","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital Universitario de la Princesa Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Segaert","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital Leuven Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Freeman","sequence":"additional","affiliation":[{"name":"Bunny Hill Primary Care Centre County Durham and Darlington NHS Foundation Trust &amp; Sunderland Teaching Primary Care Trust Sunderland UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Magina","sequence":"additional","affiliation":[{"name":"Department of Dermatology CHSJo\u00e3o Porto Portugal"},{"name":"Department of Pharmacology and Therapeutics Faculty of Medicine Porto University Porto Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Rigopoulos","sequence":"additional","affiliation":[{"name":"2nd Department of Dermatology University of Athens Medical School Attikon Hospital Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Thaci","sequence":"additional","affiliation":[{"name":"Comprehensive Centre for Inflammation Medicine University Hospital Schleswig\u2010Holstein L\u00fcbeck Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,5,22]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041320"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.02.039"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.2001.00832.x"},{"key":"e_1_2_8_5_1","unstructured":"National Psoriasis Foundation.Statistics. [WWW document].2016URLhttp:\/\/www.psoriasis.org(last accessed: 19 August 2016)."},{"key":"e_1_2_8_6_1","first-page":"1","article-title":"Current challenges and emerging drug delivery strategies for the treatment of psoriasis","volume":"25","author":"Hoffman MB","year":"2016","journal-title":"Expert Opin Drug Deliv"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61909-7"},{"issue":"2","key":"e_1_2_8_8_1","first-page":"S36","article-title":"Topical therapies for psoriasis: improving management strategies and patient adherence","volume":"35","author":"Stein Gold LF","year":"2016","journal-title":"Semin Cutan Med Surg"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2016.1202115"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpm.2016.02.004"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.12.018"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13614"},{"key":"e_1_2_8_13_1","unstructured":"International Society of Drug Bulletins.ISDB declaration on therapeutic advance in the use of medicines. [WWW document]2001. URLhttp:\/\/www.isdbweb.org\/documents\/uploads\/Declaration\/ISDB-decl-english.pdf(last accessed: 19 August 2016)."},{"key":"e_1_2_8_14_1","volume-title":"Fitzpatrick's Dermatology in General Medicine","author":"Goldsmith LA","year":"2012"},{"key":"e_1_2_8_15_1","first-page":"12","article-title":"Recent advances in novel topical drug delivery system","volume":"1","author":"Bhowmik D","year":"2012","journal-title":"Pharma Innov"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.4081\/dr.2014.5451"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-016-0125-6"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12372"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12745"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2012.711756"},{"key":"e_1_2_8_21_1","unstructured":"FDA Guidance for Industry.Patient\u2010reported outcome measures: use in medical product development to support labeling claims. [WWW document]2009. URLhttp:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/UCM193282.pdf(last accessed: 19 August 2016)."},{"key":"e_1_2_8_22_1","first-page":"407","article-title":"Medication formulation affects quality of life: a randomized single\u2010blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis","volume":"72","author":"Bergstrom KG","year":"2003","journal-title":"Cutis"},{"key":"e_1_2_8_23_1","first-page":"201","article-title":"Clobetasol propionate lotion in the treatment of moderate to severe plaque\u2010type psoriasis","volume":"74","author":"Decroix J","year":"2004","journal-title":"Cutis"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546630510041060"},{"key":"e_1_2_8_25_1","first-page":"328","article-title":"Short\u2010term safety assessment of clobetasol propionate 0.05% shampoo: hypothalamic\u2010pituitary\u2010adrenal axis suppression, atrophogenicity, and ocular safety in subjects with scalp psoriasis","volume":"5","author":"Andres P","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546630802449104"},{"key":"e_1_2_8_27_1","first-page":"47","article-title":"Calcipotriol ointment versus cream in psoriasis vulgaris","volume":"23","author":"Duweb G","year":"2003","journal-title":"Int J Clin Pharmacol Res"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2006.01387.x"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.2165\/11539780-000000000-00000"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.2165\/11634710-000000000-00000"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S35046"},{"key":"e_1_2_8_32_1","first-page":"304","article-title":"Calcipotriene 0.005%\u2013betamethasone dipropionate 0.064% ointment versus topical suspension in the treatment of plaque psoriasis: a randomized pilot study of patient preference","volume":"94","author":"Sandoval LF","year":"2014","journal-title":"Cutis"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12387"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13230"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-015-0269-7"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2015.1083935"},{"key":"e_1_2_8_37_1","first-page":"951","article-title":"Aerosol foam formulation of fixed combination calcipotriene plus betamethasone dipropionate is highly efficacious in patients with psoriasis vulgaris: pooled data from three randomized controlled studies","volume":"15","author":"Stein Gold L","year":"2016","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13859"},{"issue":"1","key":"e_1_2_8_39_1","article-title":"More rapid improvement in quality of life with fixed combination calcipotriene plus betamethasone dipropionate aerosol foam versus topical suspension (PSO\u2010ABLE study in patients with psoriasis vulgaris)","volume":"74","author":"Paul C","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_8_40_1","first-page":"154","article-title":"DFD\u201001, a novel medium potency betamethasone dipropionate 0.05% emollient spray, demonstrates similar efficacy to augmented betamethasone dipropionate 0.05% lotion for the treatment of moderate plaque psoriasis","volume":"15","author":"Fowler JF","year":"2016","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1080\/10601330701885116"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2016.0859"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.2165\/11311020-000000000-00000"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2000.00986-4.x"},{"key":"e_1_2_8_45_1","first-page":"280","article-title":"The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient\u2010membership survey","volume":"137","author":"Krueger G","year":"2001","journal-title":"Arch Dermatol"},{"key":"e_1_2_8_46_1","first-page":"32","article-title":"The roles of safety and compliance in determining effectiveness of topical therapy for psoriasis","volume":"79","author":"Stein Gold L","year":"2007","journal-title":"Cutis"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04525.x"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12039"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12445"},{"key":"e_1_2_8_50_1","first-page":"258","article-title":"Disease burden and treatment adherence in psoriasis patients","volume":"92","author":"Feldman SR","year":"2013","journal-title":"Cutis"},{"key":"e_1_2_8_51_1","first-page":"570","article-title":"Are ointments better than other vehicles for corticosteroid treatment of psoriasis?","volume":"8","author":"Zivkovich AH","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04113.x"},{"key":"e_1_2_8_53_1","first-page":"46","article-title":"Assessing attributes of topical vehicles for the treatment of acne, atopic dermatitis, and plaque poriasis","volume":"94","author":"Eastman WJ","year":"2014","journal-title":"Cutis"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-016-0119-4"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2005.01329.x"},{"key":"e_1_2_8_56_1","unstructured":"HolK.Patient preference for topical psoriasis formulations. Abstract presented at the European Academy of Dermatology and Venerology congress 6\u201310 Oct 2010 Gothenburg Sweden. P572."},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.08.028"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.14277","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.14277","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.14277","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/chorus\/v1\/articles\/10.1111%2Fjdv.14277","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.14277","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:39:45Z","timestamp":1791279585000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.14277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,22]]},"references-count":56,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["10.1111\/jdv.14277"],"URL":"https:\/\/doi.org\/10.1111\/jdv.14277","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,22]]}}}